✦ LIBER ✦

Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy

✍ Scribed by Seregni, E.; Maccauro, M.; Chiesa, C.; Mariani, L.; Pascali, C.; Mazzaferro, V.; Braud, F.; Buzzoni, R.; Milione, M.; Lorenzoni, A.; Bogni, A.; Coliva, A.; Vullo, S. Lo; Bombardieri, E.

Book ID: 121573002
Publisher: Springer
Year: 2013
Tongue: English
Weight: 329 KB
Volume: 41
Category: Article
ISSN: 0340-6997
DOI: 10.1007/s00259-013-2578-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Repeated cycles of peptide receptor radi

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

✍ Dorota Pach; Anna Sowa-Staszczak; Jolanta Kunikowska; Leszek Królicki; Małgorzat 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 432 KB

Comparison of sequential planar177Lu-DOT

Comparison of sequential planar177Lu-DOTA-TATE dosimetry scans with68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy

✍ Aurora Sainz-Esteban; Vikas Prasad; Christiane Schuchardt; Carolin Zachert; José 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 444 KB

Clinical results of radionuclide therapy

Clinical results of radionuclide therapy of neuroendocrine tumours with90Y-DOTATATE and tandem90Y/177Lu-DOTATATE: which is a better therapy option?

✍ Jolanta Kunikowska; Leszek Królicki; Alicja Hubalewska-Dydejczyk; Renata Mikołaj 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 487 KB

## Purpose Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). A combination treatment using the high-energy ^90^Y beta emitter for larger lesions and the lower energy ^177^Lu for